In people: TRI-04

Our first in-human pilot: TRI-04 raised the gut's butyrate-producing bacteria within three days.

In living human gut communities: TRI-01

Dosed into living human gut communities, TRI-01 raised its four target species, the lead one in every community tested:

SpeciesFold change
Agathobaculum butyriciproducens45×
Coprococcus catus13×
Anaerostipes hadrus8×
Faecalibacillus intestinalisincreased
1× 3× 9× 15× 45× fold induction (log) the gut community → all four targets up Agathobaculum butyriciproducens — ×45 ×45 Coprococcus catus — ×13 ×13 Anaerostipes hadrus — ×8 ×8 Faecalibacillus intestinalis — increased ↑
  • Agathobaculum butyriciproducens×45
  • Coprococcus catus×13
  • Anaerostipes hadrus×8
  • Faecalibacillus intestinalis↑
Living human gut communities Fold change of each target species at end point, TRI-01 dosed on its own.

The species: published science

A. butyriciproducens reduced amyloid-β burden and improved cognition (Lee 2020), matured synapses (Song 2024) and protected dopamine neurons (Bok 2022) in published animal models. That record is why it leads our target set.

The patent office

The EPO's Search Opinion on our priority application:

"…plausible that a composition able to promote the abundance of A. butyriciproducens may be effective for treating cognitive impairment due to aging and Alzheimer's disease."

Next

Controlled human studies on both products: TRI-04 for gut barrier and inflammatory response, TRI-01 for gut health and then memory, mental performance and mood in healthy adults. Designs are shared with partners under confidentiality.

How it works Quality & manufacturing
What stage is the evidence at?
TRI-04 has a first in-human pilot: the gut's butyrate-producing bacteria rose within three days. TRI-01 raised its four target species in living human gut communities. Controlled human studies on both come next.
What can a brand claim today?
Gut-health structure-function claims at launch. TRI-04 then adds gut barrier and a healthy inflammatory response; TRI-01 adds memory, mental performance and mood.
What did the EPO say?
That it is "plausible that a composition able to promote the abundance of A. butyriciproducens may be effective for treating cognitive impairment due to aging and Alzheimer's disease."
What is a living human gut community?
Primary human stool, kept alive under gut conditions and dosed with the product. It is the industry-standard way to measure how an ingredient moves named species before a human trial.
At what dose was the effect measured?
At the intake the product is designed for. Dose detail for each product is on its own page.